Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Horizon Therapeutics Plunges Following Earnings, Revenue Miss - 'Concerns Realized'
August 3, 2022 4:21 PM EDTHorizon Therapeutics (NASDAQ: HZNP) plunged over 18% Wednesday after the company reported earnings, missing analyst profit and revenue estimates.
The biopharmaceutical company posted EPS of $1.07, $0.26 below analyst forecasts of $1.33, while revenue for the quarter came in at $876.4 million versus the consensus estimate of $936.11 million.
Despite the miss, the company's CEO was positive. "Double-digit net sales growth in our orphan segment drove our second-quarter... More
Horizon Therapeutics (HZNP) PT Lowered to $138 at Stifel
August 3, 2022 12:51 PM EDTStifel analyst Annabel Samimy lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $138.00 (from $140.00) while maintaining a Buy rating.
The analyst commented, "Concerns into 2Q22 were realized on a revenues miss of $876.4mn/Cons. $938.8mn, Adj. EBITDA of $306.6mn/Cons. $379.3mn,... More
Horizon Therapeutics (HZNP) PT Lowered to $140 at Cowen
August 3, 2022 10:51 AM EDTCowen analyst Ken Cacciatore lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $140.00 (from $155.00) while maintaining a Outperform rating.
The analyst commented, "Tepezza Q2 was $480MM (-4% Q/Q) and the 2022 guidance has been revised. We continue to believe Tepezza's... More
